Innate Pharma to Present Lacutamab PTCL Phase 1b Design, ANKET Platform at ESMO

 

• Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma
• Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK cells by Innate’s Chief Scientific Officer, Eric Vivier, DVM, PhD,
• AstraZeneca-sponsored Phase 2 NeoCOAST study of neoadjuvant durvalumab alone or combined with novel agents, including monalizumab, in patients with resectable, early-stage non-small cell lung cancer (NSCLC) accepted for a mini-oral presentation on pharmacodynamic and circulating tumor DNA dynamics in the study

https://www.biospace.com/article/releases/innate-pharma-to-present-lacutamab-ptcl-phase-1b-design-and-anket-platform-at-esmo-2022/